Open AccessRisk Factors for Tumor Lysis Syndrome in Patients with Acute Lymphocytic Leukemia Treated in a Tertiary Care Hospital
Author(s) -
Tanjina Afrin,
Professor Dr. A B M Yunus,
Professor Dr. Abdul Aziz,
Professor Dr. Salahuddin Shah,
Amin Lutful Kabir,
Dr. Md. Adnan Hasan Masud,
Mahbuba Sharmin,
A.Q.M. Ashraful Haque
Publication year - 2022
Publication title -
scholars journal of applied medical sciences
Language(s) - English
Resource type - Journals
eISSN - 2347-954X
pISSN - 2320-6691
DOI - 10.36347/sjams.2022.v10i04.017
Subject(s) - tumor lysis syndrome , medicine , hyperphosphatemia , hyperuricemia , rasburicase , hematology , acute lymphocytic leukemia , acute leukemia , leukemia , chemotherapy , pediatrics , lymphoblastic leukemia , kidney disease , uric acid
Background: Tumor lysis syndrome (TLS) is the combination of metabolic and electrolyte abnormalities (hyperuricemia, hyperkalaemia, hyperphosphatemia, and secondary hypocalcemia) which occurs in patients with cancer spontaneously and usually after the initiation of cytotoxic treatment and it can cause serious clinical complications like acute kidney injury and cardiac arrest. Aim of the study: The aim of the study was to identify the associated risk factors of tumor lysis syndrome (TLS) in patients with Acute Lymphoblastic Leukemia (ALL) in a tertiary care hospital. Methods: This cross-sectional study was conducted by Department of Hematology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh October 2019 to September 2020. Newly diagnosed case of Acute Lymphoblastic Leukemia patients admitted in the department of Hematology in BSMMU, Dhaka during the study period. The study was approved by the local ethical committee and all patients gave their informed consent to take part in this investigation. Data were compiled and analyzed using the Statistical Program for Social Science (SPSS-21) version, and organized by using MS-Excel 2016. Results: TLS was absent in 34 and present in 17 cases. Within 3 days before chemotherapy, Hyperuricemia (>8.0 mg/dl) was found in 12(70.59%) cases and was absent in 1(2.33%) cases. Within 7 days after initiation of induction chemotherapy, Hyperuricemia (>8.0 mg/dl) was seen in 13(76.47%) cases. 12(70.59%) respondents were 50.0 x109/L) OR was 2.12 where 95% CI was lower in 0.91 and upper in 7.16. S. LDH (≥1000 U/L) OR was 13.07 and 95% CI was lower in 1.93 and upper in 101.23. Conclusion: In this ...